BCRX - BioCryst Pharmaceuticals, Inc.
| Previous close | 2.8300 |
| Open | 2.8700 |
| Bid | 2.7500 x 900 |
| Ask | 2.8500 x 1300 |
| Day's range | 2.7099 - 2.8800 |
| 52-week range | 1.3800 - 9.9500 |
| Volume | 4,730,456 |
| Avg. volume | 3,001,977 |
| Market cap | 428.284M |
| Beta (5Y monthly) | 2.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2130 |
| Earnings date | 01 Mar 2020 - 05 Mar 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.13 |
- Zacks
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Zacks
BioCryst Submits NDA for Hereditary Angioedema Candidate
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
- Zacks
Implied Volatility Surging for BioCryst (BCRX) Stock Options
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Simply Wall St.
Imagine Owning BioCryst Pharmaceuticals (NASDAQ:BCRX) And Trying To Stomach The 80% Share Price Drop
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -60.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolBiocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2019.
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Here's Why BioCryst Pharmaceuticals Is Soaring Today
A hedge fund disclosed a sizable stake in the company.
- Motley Fool
Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
Tough conditions for these companies left them out of the day's rally.
- Motley Fool
Here's Why BioCryst Pharmaceuticals Collapsed Today
This is a case study of when a successful phase 3 trial isn't successful enough.
- Zacks
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
Motley FoolBiocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2019.
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
BioCryst: 1Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Zacks
Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
- Simply Wall St.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): What Can We Expect From This High Growth Stock?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its latestRead More...
Motley FoolBiocryst Pharmaceuticals Inc (BCRX) Q4 2018 Earnings Conference Call Transcript
BCRX earnings call for the period ending December 31, 2018.
